April 15 (Reuters) - U.S.-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent board directors, the Financial Times reported on Monday.

Shah Capital also wants a pivot in the biotech company's sales strategy for its Covid-19 shot, which is based on traditional vaccine technology, to target older people unnerved by rare side effects associated with mRNA jabs from Pfizer and Moderna, FT reported citing a letter. (Reporting by Disha Mishra in Bengaluru; Editing by Mrigank Dhaniwala)